(ASTE) for the treatment of patients with Duchenne muscular dystrophy (DMD) with AGAMREE under a Named Patient Program. The agreement enables ASTE, a pioneering healthcare distributor with over four ...

In particular, the company's main value drivers address myotonic dystrophy type 1 [DM1], Duchenne muscular dystrophy [DMD], ...

JPMorgan sees a long-term buying opportunity after Sarepta (SRPT) shares were under pressure last week post earnings. Near-term, if one ...

Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...

Neurotech has appointed Dr Anthony Filippis as its managing director to steer the company as it progresses clinical testing ...

Saudi researchers from Qassim University identified Bethlem Myopathy, a rare genetic disorder. The scientific discovery sheds ...

Dubai: A Saudi research team from Qassim University has discovered an extremely rare genetic disorder, Bethlem Myopathy, for ...

According to the Mayo Clinic, muscular dystrophy is a group of diseases that cause loss of muscle mass and progressive ...

Analyst Joseph Schwartz from Leerink Partners maintained a Buy rating on Solid Biosciences (SLDB – Research Report) and keeping the price ...

WHAT IT'S ABOUT The documentary "The Remarkable Life of Ibelin" tells the story of Mats Steen, a Norwegian man with Duchenne ...

Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...

Columnist Betty Vertin wishes she could take away the pain over the milestones in the teenage years her sons with DMD will miss.